(PSYCHIATRIC TIMES) - MedPage Today Action Points
o Explain to patients who ask that desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor, is awaiting final approval from the FDA, and is not currently on the market.
o This study was published as an abstract and presented orally at a conference. These data and conclusions should be considered to be preliminary until they have been published in a peer-reviewed publication.
SAN DIEGO, May 23 -- The novel serotonin-norepinephrine reuptake inhibitor desvenlafaxine succinate (Pristiq) was significantly superior to placebo in the treatment of anxiety symptoms in depression, results of a pooled analysis showed.
In seven randomized, placebo controlled studies, patients on desvenlafaxine had significantly greater improvement from baseline to week eight, compared with placebo, on anxiety items of the 17-item Hamilton Depression Rating Scale, reported Karen A. Tourian, M.D., and colleagues from Wyeth, maker of Pristiq.
Patients also showed significantly greater improvement in total score on the Covi Anxiety Scale, they said at the American Psychiatric Association meeting here.
For full article, please visit: